Candriam Luxembourg S.C.A. boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 14.4% during the second quarter, Holdings Channel reports. The firm owned 96,317 shares of the pharmacy operator’s stock after buying an additional 12,096 shares during the period. Candriam Luxembourg S.C.A.’s holdings in CVS Health Corporation were worth $9,222,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the stock. East Coast Asset Management LLC. increased its stake in CVS Health Corporation by 0.3% in the first quarter. East Coast Asset Management LLC. now owns 2,424 shares of the pharmacy operator’s stock worth $251,000 after buying an additional 8 shares during the period. Palladium Partners LLC increased its stake in CVS Health Corporation by 1.0% in the second quarter. Palladium Partners LLC now owns 3,724 shares of the pharmacy operator’s stock worth $356,000 after buying an additional 38 shares during the period. Harvest Capital Management Inc. increased its stake in CVS Health Corporation by 0.8% in the second quarter. Harvest Capital Management Inc. now owns 5,195 shares of the pharmacy operator’s stock worth $497,000 after buying an additional 40 shares during the period. Adirondack Trust Co. increased its stake in CVS Health Corporation by 0.4% in the second quarter. Adirondack Trust Co. now owns 13,787 shares of the pharmacy operator’s stock worth $1,320,000 after buying an additional 50 shares during the period. Finally, St. Johns Investment Management Company LLC increased its stake in CVS Health Corporation by 0.5% in the second quarter. St. Johns Investment Management Company LLC now owns 11,401 shares of the pharmacy operator’s stock worth $1,092,000 after buying an additional 58 shares during the period. 80.96% of the stock is owned by hedge funds and other institutional investors.
Shares of CVS Health Corporation (NYSE:CVS) traded down 0.10% during trading on Friday, reaching $86.40. The company’s stock had a trading volume of 4,346,345 shares. The company’s 50-day moving average is $91.41 and its 200-day moving average is $96.91. The company has a market capitalization of $92.12 billion, a P/E ratio of 19.88 and a beta of 0.83. CVS Health Corporation has a 12 month low of $85.89 and a 12 month high of $106.67.
CVS Health Corporation (NYSE:CVS) last released its earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. CVS Health Corporation had a return on equity of 15.86% and a net margin of 2.88%. The business had revenue of $43.70 billion for the quarter, compared to the consensus estimate of $44.28 billion. During the same period last year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. On average, analysts forecast that CVS Health Corporation will post $5.86 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, November 3rd. Investors of record on Monday, October 24th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.08%.
A number of equities research analysts have issued reports on the company. Deutsche Bank AG boosted their price target on CVS Health Corporation from $99.00 to $105.00 and gave the company a “hold” rating in a research report on Wednesday, June 22nd. Argus reaffirmed a “buy” rating and issued a $120.00 target price on shares of CVS Health Corporation in a research report on Thursday, August 4th. Leerink Swann reaffirmed a “buy” rating on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Zacks Investment Research raised CVS Health Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Mizuho upped their target price on CVS Health Corporation from $108.00 to $111.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $112.11.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.